
-
BridgeBio Pharma Inc NasdaqGS:BBIO BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Location: 3160 Porter Drive, Palo Alto, CA, 94304, United States | Website: https://bridgebio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
7.941B
Cash
540.6M
Avg Qtr Burn
-125.1M
Short % of Float
16.02%
Insider Ownership
4.95%
Institutional Own.
92.62%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NULIBRY (Fosdenopterin) (BBP-870/ORGN001) Details Molybdenum cofactor deficiency type A | Approved Quarterly sales | |
Attruby™ (Acoramidis) (AG10) Details Transthyretin Amyloid Cardiomyopathy | Approved Quarterly sales | |
Infigratinib Details Achondroplasia | Phase 3 Data readout | |
BBP-418 Details Limb-Girdle Muscular Dystrophy | Phase 3 Data readout | |
Phase 3 Data readout | ||
Infigratinib Details Hypochondroplasia | Phase 2 Data readout | |
BBP-398 + OPDIVO Details Solid tumor/s, Lung cancer, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
BBP- 812 Details Canavan disease | Phase 1/2 Update | |
BBO-8520 (KRASG12C inhibitor) Details Non-small cell lung carcinoma, Lung cancer, Solid tumor/s | Phase 1 Data readout | |
BBO-10203 Details Hyperglycemia | IND Submission | |
BBP-631 Details Congenital adrenal hyperplasia | Failed Discontinued | |
TRUSELTIQ (infigratinib) Details Cholangiocarcinoma | Failed Discontinued |